sarpogrelate has been researched along with Active Hyperemia in 1 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " Forearm blood flow (FBF) and leg blood flow (LBF) responses to reactive hyperemia (RH) and sublingual administration of nitroglycerin (NTG) were measured using strain-gauge plethysmography." | 5.12 | Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. ( Chayama, K; Goto, C; Higashi, Y; Miyazaki, M; Orihashi, K; Sanada, H; Sueda, T; Yoshizumi, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyazaki, M | 1 |
| Higashi, Y | 1 |
| Goto, C | 1 |
| Chayama, K | 1 |
| Yoshizumi, M | 1 |
| Sanada, H | 1 |
| Orihashi, K | 1 |
| Sueda, T | 1 |
1 trial available for sarpogrelate and Active Hyperemia
| Article | Year |
|---|---|
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Arterial Occlusive Diseases; Biomarkers; Endothelium, | 2007 |